GILEAD SCIENCES IS ON AN FDA APPROVAL HOT STREAK . SHOULD YOU BUY THE STOCK LIKE THERE NO TOMORROW ?

What happened: Gilead Sciences ($GILD) has received several FDA approvals and label expansions, including Bixlenvo for HIV, a first-line Trodelvy indication in metastatic triple-negative breast cancer, and Hepcludex for chronic hepatitis delta virus. Key numbers: Q2 revenue $7.8 billion, up 10% year over year. Why it matters: The article states the approvals should help revenue and earnings over the medium term as Veklury's impact fades, and that Bixlenvo helps solidify Gilead's HIV leadership. It calls the company an attractive dividend payer for long-term investors.

Gilead Sciences ($GILD) has received several FDA approvals and label expansions, including Bixlenvo for HIV, a first-line Trodelvy indication in metastatic triple-negative breast cancer, and Hepcludex for chronic hepatitis delta virus.

The article states the approvals should help revenue and earnings over the medium term as Veklury's impact fades, and that Bixlenvo helps solidify Gilead's HIV leadership. It calls the company an attractive dividend payer for long-term investors.